Nizatidine for prevention of weight gain with olanzapine

A double-blind placebo-controlled trial

Patrizia Cavazzoni, Yoko Tanaka, Suraja M. Roychowdhury, Alan Breier, David B. Allison

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Weight gain is associated with treatment with olanzapine and other psychotropic agents. Nizatidine, a histamine H-2 receptor antagonist, has been proposed to have weight-reducing effects. This double-blind trial evaluated the efficacy of nizatidine in limiting weight gain in patients with schizophrenia and related disorders who were treated with olanzapine for up to 16 weeks. After an initial screening period, 175 patients were randomized to receive olanzapine (5-20 mg) with either placebo or nizatidine (150 mg b.i.d. or 300 mg b.i.d.). Significantly less weight gain was observed on average at weeks 3 and 4 with olanzapine+nizatidine 300 mg b.i.d. (P

Original languageEnglish (US)
Pages (from-to)81-85
Number of pages5
JournalEuropean Neuropsychopharmacology
Volume13
Issue number2
DOIs
StatePublished - Mar 2003

Fingerprint

olanzapine
Nizatidine
Weight Gain
Placebos
Histamine
Schizophrenia
Weights and Measures

Keywords

  • H-2 blockade
  • Nizatidine
  • Olanzapine
  • Weight gain

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

Nizatidine for prevention of weight gain with olanzapine : A double-blind placebo-controlled trial. / Cavazzoni, Patrizia; Tanaka, Yoko; Roychowdhury, Suraja M.; Breier, Alan; Allison, David B.

In: European Neuropsychopharmacology, Vol. 13, No. 2, 03.2003, p. 81-85.

Research output: Contribution to journalArticle

Cavazzoni, Patrizia ; Tanaka, Yoko ; Roychowdhury, Suraja M. ; Breier, Alan ; Allison, David B. / Nizatidine for prevention of weight gain with olanzapine : A double-blind placebo-controlled trial. In: European Neuropsychopharmacology. 2003 ; Vol. 13, No. 2. pp. 81-85.
@article{46a2b81548924793970851edef6e452a,
title = "Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial",
abstract = "Weight gain is associated with treatment with olanzapine and other psychotropic agents. Nizatidine, a histamine H-2 receptor antagonist, has been proposed to have weight-reducing effects. This double-blind trial evaluated the efficacy of nizatidine in limiting weight gain in patients with schizophrenia and related disorders who were treated with olanzapine for up to 16 weeks. After an initial screening period, 175 patients were randomized to receive olanzapine (5-20 mg) with either placebo or nizatidine (150 mg b.i.d. or 300 mg b.i.d.). Significantly less weight gain was observed on average at weeks 3 and 4 with olanzapine+nizatidine 300 mg b.i.d. (P",
keywords = "H-2 blockade, Nizatidine, Olanzapine, Weight gain",
author = "Patrizia Cavazzoni and Yoko Tanaka and Roychowdhury, {Suraja M.} and Alan Breier and Allison, {David B.}",
year = "2003",
month = "3",
doi = "10.1016/S0924-977X(02)00127-X",
language = "English (US)",
volume = "13",
pages = "81--85",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Nizatidine for prevention of weight gain with olanzapine

T2 - A double-blind placebo-controlled trial

AU - Cavazzoni, Patrizia

AU - Tanaka, Yoko

AU - Roychowdhury, Suraja M.

AU - Breier, Alan

AU - Allison, David B.

PY - 2003/3

Y1 - 2003/3

N2 - Weight gain is associated with treatment with olanzapine and other psychotropic agents. Nizatidine, a histamine H-2 receptor antagonist, has been proposed to have weight-reducing effects. This double-blind trial evaluated the efficacy of nizatidine in limiting weight gain in patients with schizophrenia and related disorders who were treated with olanzapine for up to 16 weeks. After an initial screening period, 175 patients were randomized to receive olanzapine (5-20 mg) with either placebo or nizatidine (150 mg b.i.d. or 300 mg b.i.d.). Significantly less weight gain was observed on average at weeks 3 and 4 with olanzapine+nizatidine 300 mg b.i.d. (P

AB - Weight gain is associated with treatment with olanzapine and other psychotropic agents. Nizatidine, a histamine H-2 receptor antagonist, has been proposed to have weight-reducing effects. This double-blind trial evaluated the efficacy of nizatidine in limiting weight gain in patients with schizophrenia and related disorders who were treated with olanzapine for up to 16 weeks. After an initial screening period, 175 patients were randomized to receive olanzapine (5-20 mg) with either placebo or nizatidine (150 mg b.i.d. or 300 mg b.i.d.). Significantly less weight gain was observed on average at weeks 3 and 4 with olanzapine+nizatidine 300 mg b.i.d. (P

KW - H-2 blockade

KW - Nizatidine

KW - Olanzapine

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=0037338491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037338491&partnerID=8YFLogxK

U2 - 10.1016/S0924-977X(02)00127-X

DO - 10.1016/S0924-977X(02)00127-X

M3 - Article

VL - 13

SP - 81

EP - 85

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 2

ER -